Patents by Inventor Bernd Duesterberg
Bernd Duesterberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10532025Abstract: The invention relates to a method for contraception and for reducing menstrual problems and inducing amenorrhea, wherein an intrauterine delivery device is used for the controlled release of a combination of progestogen or a drug having a progestogenic activity and at least one therapeutically active substance capable of preventing or suppressing abnormal and/or irregular endometrial bleeding over a prolonged period of time.Type: GrantFiled: May 18, 2018Date of Patent: January 14, 2020Assignee: Bayer OyInventors: Bernd Duesterberg, Manja Ahola, Jyrki Pihlaja, Heikki Lyytikäinen, Harri Jukarainen, Satu Kleemola, Tero Parkatti, Tuula Valo, Ina Gröticke, Bernhard Lindenthal, Ulrike Fuhrmann
-
Publication number: 20180263899Abstract: The invention relates to a method for contraception and for reducing menstrual problems and inducing amcnorrhca, whcrcin an intrauterine delivery device is used for the controlled release of a combination of progestogen or a drug having a progestogenic activity and at least one therapeutically active substance capable of preventing or suppressing abnormal and/or irregular endometrial bleeding over a prolonged period of time.Type: ApplicationFiled: May 18, 2018Publication date: September 20, 2018Applicant: Bayer OyInventors: Bernd Duesterberg, Manja Ahola, Jyrki Pihlaja, Heikki Lyytikäinen, Harri Jukarainen, Satu Kleemola, Tero Parkatti, Tuula Valo, Ina Gröticke, Bernhard Lindenthal, Ulrike Fuhrmann
-
Patent number: 9999592Abstract: The invention relates to a method for contraception and for reducing menstrual problems and inducing amenorrhea, wherein an intrauterine delivery device is used for the controlled release of a combination of progestogen or a drug having a progestogenic activity and at least one therapeutically active substance capable of preventing or suppressing abnormal and/or irregular endometrial bleeding over a prolonged period of time.Type: GrantFiled: July 3, 2013Date of Patent: June 19, 2018Assignee: Bayer OyInventors: Bernd Duesterberg, Manja Ahola, Jyrki Pihlaja, Heikki Lyytikäinen, Harri Jukarainen, Satu Kleemola, Tero Parkatti, Tuula Valo, Ina Gröticke, Bernhard Lindenthal, Ulrike Fuhrmann
-
Publication number: 20170312219Abstract: The invention is related to an improved method of contraception, for preventing or suppressing abnormal and/or irregular endometrial bleeding and achieving a rapid induction of amenorrhea by using an intrauterine delivery system comprising controlled release levonorgestrel over a prolonged period of time and at a therapeutic level required for contraception, and a sufficient amount of NSAID capable of suppressing abnormal and/or irregular endometrial bleedingType: ApplicationFiled: July 14, 2017Publication date: November 2, 2017Applicant: Bayer OyInventors: Bernd Duesterberg, Manja Ahola, Jyrki Pihlaja, Heikki Lyytikäinen, Harri Jukarainen, Satu Kleemola, Tero Parkatti, Tuula Valo, Ina Gröticke, Bernhard Lindenthal, Ulrike Fuhrmann
-
Publication number: 20140127280Abstract: The invention relates to a method for contraception and for reducing menstrual problems and inducing amenorrhea, wherein an intrauterine delivery device is used for the controlled release of a combination of progestogen or a drug having a progestogenic activity and at least one therapeutically active substance capable of preventing or suppressing abnormal and/or irregular endometrial bleeding over a prolonged period of time.Type: ApplicationFiled: July 3, 2013Publication date: May 8, 2014Inventors: Bernd Duesterberg, Manja Ahola, Jyrki Pihlaja, Heikki Lyytikäinen, Harri Jukarainen, Satu Kleemola, Tero Parkatti
-
Patent number: 8501720Abstract: A method of treatment of dysmenorrhea in the context of oral contraception characterized by daily administration of ethinylestradiol and drospirenone in an extended regimen.Type: GrantFiled: August 1, 2005Date of Patent: August 6, 2013Assignee: Bayer Pharma AGInventors: Renate Heithecker, Bernd Duesterberg
-
Patent number: 8071577Abstract: The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenone. The multiphase preparation is characterized by a first phase consisting of 2 daily dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenone and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenone, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.Type: GrantFiled: April 15, 2005Date of Patent: December 6, 2011Assignee: Bayer Pharma AktiengesellschaftInventors: Jan Endrikat, Bernd Duesterberg
-
Publication number: 20110146693Abstract: The invention relates to a method for contraception and for reducing menstrual problems and inducing amenorrhea, wherein an intrauterine delivery device is used for the controlled release of a combination of progestogen or a drug having a progestogenic activity and at least one therapeutically active substance capable of preventing or suppressing abnormal and/or irregular endometrial bleeding over a prolonged period of time.Type: ApplicationFiled: July 1, 2009Publication date: June 23, 2011Inventors: Bernd Duesterberg, Manja Ahola, Jyrki Pihlaja, Heikki Lyytikäinen, Harri Jukarainen, Satu Kleemola, Tero Parkatti
-
Publication number: 20110124612Abstract: The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenon. The multiphase prepration is characterized by a first phase consisting of 2 daily dose dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenon and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenon, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.Type: ApplicationFiled: February 4, 2011Publication date: May 26, 2011Inventors: Jan ENDRIKAT, Bernd Duesterberg
-
Publication number: 20100173877Abstract: The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenon. The multiphase prepration is characterized by a first phase consisting of 2 daily dose dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenon and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenon, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.Type: ApplicationFiled: March 18, 2010Publication date: July 8, 2010Inventors: Jan Endrikat, Bernd Duesterberg
-
Publication number: 20080234240Abstract: A pharmaceutical preparation to obtain a continuous hormonal treatment over a desired period of time longer than 21-28 days comprising a first composition containing at least one estrogen and/or at least one progestin in a predetermined amount to be administered in the first 21-28 days and a second composition which contains at least one estrogen and/or at least one progestin in a predetermined amount higher than the amount of the first composition and comprises a mono or multiphase sequence of pharmaceutical dosages.Type: ApplicationFiled: November 20, 2004Publication date: September 25, 2008Applicant: SCHERING AGInventors: Bernd Düsterberg, Jan Endrikat, Rolf Schurmann
-
Publication number: 20070259840Abstract: The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenon. The multiphase preparation is characterized by a first phase consisting of 2 daily dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenon and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenon, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.Type: ApplicationFiled: April 15, 2005Publication date: November 8, 2007Applicant: SCHERING AGInventors: Jan Endrikat, Bernd Duesterberg
-
Publication number: 20060128679Abstract: A method of treatment of dysmenorrhea in the context of oral contraception characterized by daily administration of ethinylestradiol and drospirenone in an extended regimen.Type: ApplicationFiled: August 1, 2005Publication date: June 15, 2006Inventors: Renate Heithecker, Bernd Duesterberg
-
Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen
Patent number: 6995149Abstract: The present invention relates to a female mammal contraceptive process consisting of the sequential administration for at least 28 days of (a) a gestagen in an ovulation-preventing dose for at least 28 days in combination with (b) a natural oestrogen for 5 to 10 days at the end of the sequential dosage of at least 28 days, and a contraception kit.Type: GrantFiled: December 20, 1996Date of Patent: February 7, 2006Assignee: Schering AGInventors: Jan Endrikat, Bernd Düsterberg, Pia Reilhac -
Publication number: 20050171071Abstract: The present invention relates to methods of increasing likelihood of conception, treatment of low fecundity and/or providing menstrual cycle control without suppressing ovulation in a female comprising administering an effective dose of at least one estrogen and at least one progestin within a treatment period of at least 21 days to 35 days or multiple periods thereof. Furthermore, the invention relates to the combination of at least one estrogen and at least one progestin for the preparation of a medicament to be used in the abovementioned indications.Type: ApplicationFiled: January 3, 2005Publication date: August 4, 2005Inventors: Jan Endrikat, Bernd Duesterberg, Jens Wessel, Ilka Schellschmidt
-
Publication number: 20050113350Abstract: A pharmaceutical preparation to obtain a continuous hormonal treatment over a desired period of time longer than 21-28 days comprising a first composition containing at least one estrogen and/or at least one progestin in a predetermined amount to be administered in the first 21-28 days and a second composition which contains at least one estrogen and/or at least one progestin in a predetermined amount higher than the amount of the first composition and comprises a mono or multiphase sequence of pharmaceutical dosages.Type: ApplicationFiled: November 26, 2003Publication date: May 26, 2005Inventors: Bernd Duesterberg, Jan Endrikat, Rolf Schuermann
-
Patent number: RE37564Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 2.5 to 3.0 mg of drospirenone and 0.1 to 0.2 1 to 2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.Type: GrantFiled: February 15, 2000Date of Patent: February 26, 2002Assignee: Schering AktiengesellschaftInventors: Jürgen Spona, Bernd Düsterberg, Frank Lüdicke
-
Patent number: RE37838Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.Type: GrantFiled: February 15, 2000Date of Patent: September 10, 2002Assignee: Schering AktiengesellschaftInventors: Jürgen Spona, Bernd Düsterberg, Frank Lüdicke
-
Patent number: RE38253Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 2.5 to 3.0 mg of drospirenone and 0.1 to 0.2 1 to 2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.Type: GrantFiled: February 25, 2002Date of Patent: September 16, 2003Assignee: Schering AktiengesellschaftInventors: Jürgen Spona, Bernd Düsterberg, Frank Lüdicke